2013 Fiscal Year Final Research Report
Preclinical study for Head and Neck Cancer using rAAV-GALR2
| Project/Area Number |
23592539
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Otorhinolaryngology
|
|---|
| Research Institution | Jichi Medical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
ICHIMUR Keiichi 自治医科大学, 医学部, 教授 (00010471)
MIZUKAMI Hiroaki 自治医科大学, 医学部, 准教授 (20311938)
UEHARA Takayuki 琉球大学, 医学部, 助教 (00644402)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Keywords | 遺伝子治療 / GALR２ / 癌抑制遺伝子 / 頭頸部癌 / AAV |
|---|
| Research Abstract |
Galanin and its receptors, GALR1 and GALR2, are known tumor suppressors and potential therapeutic targets in head and neck squamous cell carcinoma (HNSCC). In this study, we first transduced HEp-2 and KB cell lines using a recombinant adeno-associated virus (rAAV)-green fluorescent protein (GFP) vector and confirmed a high GFP expression rate (>90%) in both cell lines. Next, we demonstrated that GALR2 expression in the presence of galanin suppressed cell viability to 40-60% after 72 h in both cell lines. Additionally, the annexin V-positive rate and sub-G0/G1 phase population were significantly elevated in HEp-2 cells (mock vs GALR2: 12.3 vs 25.0% (P < 0.01) and 9.1 vs 32.0% (P < 0.05), respectively) after 48 h. These changes were also observed in KB cells, although to a lesser extent. Furthermore, in HEp-2 cells, GALR2-mediated apoptosis was caspase-independent, involving downregulation of ERK1/2, followed by induction of the pro-apoptotic Bcl-2 protein, Bim.
|
-
[Journal Article] Novel anti-tumor mechanism of galanin receptor type 2 in head and neck squamous cell carcinoma cells2014
Author(s)
Uehara T, Kanazawa T, Mizukami H, Uchibori R, Tsukahara T, Urabe M, Kume A, Misawa K, Carey TE, Suzuki M, Ichimura K, Ozawa K
-
Journal Title
Cancer Sci
Volume: 105
Pages: 72-80
-
-
-
-
